FDA Okays Sound-Wave Tissue Blaster: No Heat, All Zap!
Published Date: 10/6/2026
Rule
Summary
The FDA is officially classifying the focused ultrasound system for non-thermal, mechanical tissue ablation as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the device safer and easier to get to patients, boosting innovation and cutting red tape. The new classification is effective October 6, 2026, but has been in effect since October 6, 2023, affecting manufacturers and patients alike.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Device moved to Class II (lower hurdle)
The FDA has classified the focused ultrasound system for non-thermal, mechanical tissue ablation as Class II (special controls). This classification became applicable on October 6, 2023 and the order is effective October 6, 2026, and the Agency says this will reduce regulatory burdens and help get the device to patients faster.
Device and future products must use 510(k) pathway
Because FDA classified this device under the De Novo process, this device type can serve as a predicate so other sponsors may use the less burdensome 510(k) process rather than a De Novo request or premarket approval. The order also states that focused ultrasound systems for non-thermal, mechanical tissue ablation are subject to premarket notification requirements under section 510(k).
Required special controls impose testing and documentation
To be marketed in this classification, manufacturers must meet special controls including clinical performance testing, animal performance testing, and non-clinical performance testing with specific requirements (for example: acoustic characterization, minimum drive voltages to sustain a bubble cloud, validation of mechanisms preventing adverse thermal effects, real-time monitoring, treatment-zone validation, and mechanisms to pause/terminate ablation). The order also requires electrical safety/electromagnetic compatibility testing, biocompatibility, software validation, and human factors testing.
Labeling must include specific patient safety warnings
Labels must include a warning that focused ultrasound ablation should only be used in patients with sufficient functional reserve to withstand planned tissue destruction, a statement that the device has not been evaluated for treatment of any specific disease or condition, and a detailed summary of the clinical testing with the device. These labeling items are required by the final order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
Previous / Next Documents
Previous: 2026-20435, Reef Fish Fishery of the Gulf of America; Amendment 62
Starting October 2, 2026, new rules change how much red grouper fishermen in the Gulf of America can catch and how the catch is shared. Plus, the winter break for catching shallow-water grouper is gone, so anglers get more fishing days. These updates help keep fish healthy while giving fishermen and fish lovers better chances to enjoy the Gulf’s reef fishery.
Next: 2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.